Detalhe da pesquisa
1.
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.
Eur J Neurol
; 30(7): 1945-1956, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35837793
2.
Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
Blood
; 133(9): 990-992, 2019 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30593446
3.
An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma.
Pulm Pharmacol Ther
; 35: 19-27, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26474679
4.
Racial and ethnic diversity in global neuroscience clinical trials.
Contemp Clin Trials Commun
; 37: 101255, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38292216
5.
Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation.
J Neuromuscul Dis
; 11(2): 459-472, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38277300
6.
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).
J Neurol
; 270(5): 2531-2546, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36735057
7.
Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial.
Ther Adv Respir Dis
; 12: 1753466618777924, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29857783
8.
Correction to: Twoyear efficacy and safety of risdiplam in patients with type 2 or nonambulant type 3 spinal muscular atrophy (SMA).
J Neurol
; 270(5): 2547-2549, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37071150
9.
A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma.
Ther Adv Respir Dis
; 10(4): 324-37, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27185164
10.
Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations.
J Aerosol Med Pulm Drug Deliv
; 29(4): 346-61, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27104231
11.
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
Int J Chron Obstruct Pulmon Dis
; 10: 2431-8, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26648706
12.
Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: a pooled analysis.
Respir Med
; 109(2): 208-17, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25575940
13.
Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial.
Curr Med Res Opin
; 29(5): 579-88, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23368897
14.
Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study.
Adv Ther
; 29(11): 958-69, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23081745
15.
Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler.
Respir Med
; 105(5): 674-82, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21196104